Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2021 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Participate in Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two...
December 21, 2020 16:05 ET | Source: ChemoCentryx, Inc.

ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)

As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatmentThe change from baseline...
November 19, 2020 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two...
November 09, 2020 16:05 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent Highlights

-- New Drug Application (NDA) accepted for review by U.S. Food and Drug Administration (FDA) for avacopan in ANCA-associated vasculitis with PDUFA goal date of July 7, 2021 -- -- Marketing...
November 06, 2020 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Findings of ADVOCATE Phase III Trial in ANCA-Associated Vasculitis

-- Study Showed Treatment with Avacopan Achieved Statistical Superiority in Sustaining Remission at 52 Weeks and Greater Improvement in Renal Function Compared to the Prednisone Group -- MOUNTAIN...
November 03, 2020 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx and VFMCRP announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan

Companies have completed the EU regulatory application for marketing approval of avacopanRegulatory submission based on positive data from the pivotal Phase-III ADVOCATE trial of avacopan ST. GALLEN,...
November 02, 2020 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Hold Third Quarter 2020 Financial Results Conference Call on Monday, November 9, 2020

MOUNTAIN VIEW, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2020 financial results will be released after market...
October 28, 2020 16:01 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)

-- Avacopan demonstrates statistically significant dose-dependent improvement in HiSCR (Hidradenitis Suppurativa Clinical Response) vs. placebo in pre-specified Hurley Stage III (severe HS) patients...
September 17, 2020 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis

-- FDA sets PDUFA goal date of July 7, 2021 -- MOUNTAIN VIEW, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug...
September 08, 2020 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

MOUNTAIN VIEW, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the...